Ovarian Cancer Clinical Trial
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of high-dose chemotherapy.
PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors.
Full Description
OBJECTIVES:
Determine the dose-limiting toxicity of amifostine chemoprotection with peripheral blood stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid tumors or brain tumors.
Determine response or time to disease progression in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of amifostine. Patients are stratified according to age (1 to 18 vs 19 to 45 years).
All patients receive filgrastim (G-CSF) IV for 1 week. On day 6 of G-CSF administration, patients undergo peripheral blood stem cell (PBSC) harvest followed by chemotherapy.
Patients receive oral busulfan every 6 hours on days -8 to -6 followed by melphalan IV over 30 minutes on days -5 and -4 and thiotepa IV over 2 hours on days -3 and -2. Patients receive amifostine IV over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1. PBSC are reinfused on day 0.
Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed on day 50; at 3, 6, and 9 months; and at 1, 2, and 3 years post PBSC transplantation.
PROJECTED ACCRUAL: A maximum of 60 patients (30 per stratum) will be accrued for this study within 3 years.
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed high-risk or relapsed solid tumors or brain tumors, including:
Metastatic or relapsed Ewing's sarcoma
Metastatic or relapsed rhabdomyosarcoma
Refractory Wilms' tumor
Diffuse anaplastic Wilms' tumor
Stage III or IV neuroblastoma
Recurrent retinoblastoma
Metastatic or relapsed germ cell tumors
Metastatic or relapsed other soft tissue sarcomas
Small cell ovarian sarcoma
Metastatic or relapsed primitive neuroectodermal tumors of the bone
Recurrent brain tumors
Desmoplastic small round cell tumors
Recurrent or metastatic chordomas
Metastatic or relapsed hepatoblastoma
Patients receive peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression
Must have radiologic, nuclear image, or histologic verification of relapse
Age 1 to 45
Performance status:Karnofsky 70-100%
Absolute neutrophil count greater than 1,000/mm^3
Platelet count greater than 100,000/mm^3
Hemoglobin count at least 10 g/dL
Bilirubin less than 2 times upper limit of normal (ULN)
SGOT or SGPT less than 2.5 times ULN
Creatinine less than 2 times ULN
Creatinine clearance greater than 70 mL/min
Cardiac shortening fraction greater than 30%
Cardiac ejection fraction greater than 45%
At least 1 week since prior hematopoietic growth factor and recovered
At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
Recovered from any prior therapy
Exclusion Criteria:
Osteogenic sarcoma
Less than 4 months
Uncontrolled bleeding
Congestive heart failure
Uncontrolled hypertension
Asthma
Pregnant or nursing
Uncontrolled metabolic disease
Active severe infection
Allergy to aminothiol compounds
Prior bone marrow transplantation
Other concurrent investigational agents
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Minneapolis Minnesota, 55455, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.